FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Novo, Eli Lilly to dominate global pharma sales in 2025: report
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
This Unpopular Dividend Stock Is a Buy
Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Renal & Urology News3d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...
pharmaphorum1d
BMS' Opdivo stumbles in lung cancer, but could still maintain lead
Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...
pharmaphorum3d
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.
Subcutaneous options offer convenience for patients — and a valuable window for drugmakers
From weight loss to cancer drugs, subcutaneous injections are popular with patients for their convenience, potentially ...